Related Experiment Video
Updated: Jul 12, 2026
08:15
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
Published on: September 17, 2015
Candesartan cilexetil: development and preclinical studies
P Gohlke1, T Jürgensen, S von Kügelgen
1Institute of Pharmacology, Christian-Albrechts University of Kiel, Germany.
Drugs of Today (Barcelona, Spain : 1998)
|September 16, 2003
Summary
Candesartan cilexetil, an AT(1) receptor antagonist, effectively lowers blood pressure and protects organs. It demonstrates significant antihypertensive and organ protection in preclinical models, highlighting its therapeutic potential.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Nephrology
Background:
- Candesartan is a nonpeptide AT(1) receptor antagonist derived from the prodrug candesartan cilexetil.
- It exhibits potent, selective, and slow-dissociating binding to the AT(1) receptor, reducing angiotensin II (AII) effects.
- Unopposed AT(2) receptor stimulation may contribute to the overall therapeutic actions.
Purpose of the Study:
- To evaluate the antihypertensive efficacy of candesartan cilexetil.
- To assess the organ-protective effects of candesartan cilexetil in preclinical models.
- To investigate the impact of candesartan cilexetil on stroke incidence.
Main Methods:
- In vitro receptor binding and functional assays.
- In vivo studies using various animal models of hypertension (2-kidney-1-clip, 1-kidney-1-clip, SHR).
- Assessment of renin-angiotensin system parameters, blood pressure, end-organ damage (cardiac, renal), and stroke incidence.
Main Results:
- Candesartan cilexetil demonstrated dose-dependent reduction in maximal AII responses in vitro.
- It produced a slow-onset, long-lasting antihypertensive effect in animal models with no rebound.
- Significant protection against left ventricular hypertrophy, cardiac fibrosis, ischemia-reperfusion injury, renal dysfunction, and stroke was observed.
Conclusions:
- Candesartan cilexetil is an effective antihypertensive agent with a favorable pharmacokinetic profile.
- The drug offers significant end-organ protection, including cardiac and renal benefits.
- Candesartan cilexetil demonstrates potent stroke prevention capabilities in preclinical models.
Related Concept Videos
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...